JPH0419968B2 - - Google Patents
Info
- Publication number
- JPH0419968B2 JPH0419968B2 JP58135265A JP13526583A JPH0419968B2 JP H0419968 B2 JPH0419968 B2 JP H0419968B2 JP 58135265 A JP58135265 A JP 58135265A JP 13526583 A JP13526583 A JP 13526583A JP H0419968 B2 JPH0419968 B2 JP H0419968B2
- Authority
- JP
- Japan
- Prior art keywords
- dds
- leprosy
- brodimoprim
- culture
- cultures
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims description 15
- BFCRRLMMHNLSCP-UHFFFAOYSA-N brodimoprim Chemical compound COC1=C(Br)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 BFCRRLMMHNLSCP-UHFFFAOYSA-N 0.000 claims description 9
- 206010024229 Leprosy Diseases 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 230000001355 anti-mycobacterial effect Effects 0.000 claims 1
- 239000003926 antimycobacterial agent Substances 0.000 claims 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims 1
- 229960000252 brodimoprim Drugs 0.000 description 7
- 239000000725 suspension Substances 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241001147830 Mycobacterium lufu Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- -1 (4-bromo-3,5-dimethoxybenzyl)-pyridine Chemical compound 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003110 Primojel Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH4600/82A CH651473A5 (de) | 1982-07-29 | 1982-07-29 | Pharmazeutisches praeparat. |
| CH4600/82-8 | 1982-07-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5933218A JPS5933218A (ja) | 1984-02-23 |
| JPH0419968B2 true JPH0419968B2 (it) | 1992-03-31 |
Family
ID=4279115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58135265A Granted JPS5933218A (ja) | 1982-07-29 | 1983-07-26 | 抗マイコバクテリア組成物 |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JPS5933218A (it) |
| BE (1) | BE897397A (it) |
| CH (1) | CH651473A5 (it) |
| DE (1) | DE3326165A1 (it) |
| FR (1) | FR2531861B1 (it) |
| GB (1) | GB2125293B (it) |
| IT (1) | IT1171692B (it) |
| NL (1) | NL194535C (it) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK387687A (da) * | 1986-07-28 | 1988-01-29 | Warner Lambert Co | Fremstilling af farmaceutisk praeparat til behandling af infektioner med mycobacterium avium-intracellulare komplekset |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK136470B (da) * | 1973-11-08 | 1977-10-17 | Hoffmann La Roche | Analogifremgangsmåde til fremstilling af 2,4-diamino-5-benzylpyrimidinderivater eller salte deraf. |
| ZW10681A1 (en) * | 1980-06-26 | 1982-02-24 | Hoffmann La Roche | Antibacterial agents |
| GB2082063A (en) * | 1980-08-15 | 1982-03-03 | Haughey Edward | Antibacterial drug |
-
1982
- 1982-07-29 CH CH4600/82A patent/CH651473A5/de not_active IP Right Cessation
-
1983
- 1983-07-15 IT IT22089/83A patent/IT1171692B/it active
- 1983-07-19 NL NL8302579A patent/NL194535C/nl not_active IP Right Cessation
- 1983-07-20 DE DE19833326165 patent/DE3326165A1/de active Granted
- 1983-07-21 FR FR8312071A patent/FR2531861B1/fr not_active Expired
- 1983-07-26 JP JP58135265A patent/JPS5933218A/ja active Granted
- 1983-07-28 BE BE0/211250A patent/BE897397A/fr not_active IP Right Cessation
- 1983-07-28 GB GB08320438A patent/GB2125293B/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| NL194535C (nl) | 2002-07-02 |
| JPS5933218A (ja) | 1984-02-23 |
| GB8320438D0 (en) | 1983-09-01 |
| NL194535B (nl) | 2002-03-01 |
| IT8322089A0 (it) | 1983-07-15 |
| DE3326165C2 (it) | 1993-07-22 |
| DE3326165A1 (de) | 1984-04-12 |
| GB2125293A (en) | 1984-03-07 |
| BE897397A (fr) | 1984-01-30 |
| FR2531861A1 (fr) | 1984-02-24 |
| NL8302579A (nl) | 1984-02-16 |
| IT8322089A1 (it) | 1985-01-15 |
| GB2125293B (en) | 1985-11-13 |
| CH651473A5 (de) | 1985-09-30 |
| FR2531861B1 (fr) | 1987-08-28 |
| IT1171692B (it) | 1987-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Crowle et al. | Chlorpromazine: a drug potentially useful for treating mycobacterial infections | |
| Wayne et al. | Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis | |
| RU2663289C2 (ru) | Производные фенотиазина и их применение против туберкулеза | |
| Hobby et al. | In vitro and in vivo activity of streptomycin and isoniazid singly and in combination | |
| Stead et al. | Chemotherapy for tuberculosis today | |
| Jenne et al. | Correlation of in vitro and in vivo kinetics with clinical use of isoniazid, ethambutol, and rifampin | |
| UA81640C2 (ru) | Противомикобактериальные соединения, способ их получения, фармацевтическая композиция на их основе | |
| PT655249E (pt) | Moenomicina como medicamento para o tratamento de ulceras gastricas | |
| JPH0419968B2 (it) | ||
| KR890003378A (ko) | 혐기성균에 대해 항균작용을 갖는 나프티리딘 화합물 | |
| Gilbert et al. | Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis | |
| Beggs et al. | Mechanism for the pyridoxal neutralization of isoniazid action on Mycobacterium tuberculosis | |
| JP2000505808A (ja) | Ｅｌｆ５Ａ生合成の抑制方法 | |
| JPH07506804A (ja) | 痴呆の処置のためのダプソーン及びプロミン | |
| JP2650852B2 (ja) | 抗菌性配合製剤 | |
| Tsui et al. | Postantibiotic effects of amikacin and ofloxacin on Mycobacterium fortuitum | |
| KR20070007920A (ko) | 항미코박테리아성 약제학적 조성물 | |
| Gelber et al. | Effect of low-level and intermittent minocycline therapy on the growth of Mycobacterium leprae in mice | |
| Shaffer et al. | Evaluation of prolonged antibiotic therapy in mice with chronic brucella infection due to Brucella melitensis | |
| US3192113A (en) | N, n'-dialkylenediamines as antitubercular agents | |
| Wright et al. | Candidacidal activity of myeloperoxidase: therapeutic influence of the enzyme in vivo | |
| Evans et al. | Hydrazide antidepressants possess novel antileishmanial activity in vitro and in vivo | |
| Nakamura et al. | Effect of purine derivatives on Trypanosoma cruzi in vitro | |
| LG | Sulphonamides and folic acid antagonists in malaria and toxoplasmosis. | |
| IL45337A (en) | Therapeutical composition containing an isonicotinic acid hydrazide thioisonicotinic acid amide sulfones and/or sulfonamides for the treatment of mycobacterioses |